Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes

Anderson, 1996, Selective inhibition of cyclo-oxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis, J. Clin. Invest., 97, 2672, 10.1172/JCI118717

Appleton, 1994, Inducible cyclooxygenase (COX-2): a safer therapeutic target, Br. J. Rheu-matol., 33, 410, 10.1093/rheumatology/33.5.410

Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N. Engl. J. Med., 343, 1520, 10.1056/NEJM200011233432103

Brideau, 1996, A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors, Inflamm. Res., 45, 68, 10.1007/BF02265118

Crofford, 1994, Cyclooxygenase-1 and −2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids, J. Clin. Invest., 93, 1095, 10.1172/JCI117060

Cryer, 1998, Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs, Am. J. Med., 104, 413, 10.1016/S0002-9343(98)00091-6

Distel, 1996, Safety of meloxicam: a global analysis of clinical trials, Br. J. Rheumatol., 35, 68, 10.1093/rheumatology/35.suppl_1.68

Emery, 1996, Clinical implications of selective cyclooxygenase-2 inhibition, Scand. J. Rheumatol., 25, 23, 10.3109/03009749609097227

Flower, 1972, Effects of anti-inflammatory drugs on prostaglandin biosynthesis, Nat. New Biol., 238, 104, 10.1038/newbio238104a0

Glaser, 1995, Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1, Eur. J. Pharmacol., 281, 107, 10.1016/0014-2999(95)00302-2

Grossman, 1995, Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors, Inflamm. Res., 44, 253, 10.1007/BF01782978

Inagaki, 2000, Novel antiarthritic agents with 1,2-isothiazolidine-1, 1-dioxide (γ-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase, J. Med. Chem., 43, 2040, 10.1021/jm9906015

Kawai, 1998, Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration, Inflamm. Res., 47, S102, 10.1007/s000110050291

Kawai, 1989, Interaction of RU 486, a glucocorticoid and progestin antagonist with human circulating mononuclear leukocytes, Am. J. Med. Sci., 298, 167, 10.1097/00000441-198909000-00004

Kawai, 1998, Comparison of cyclooxygenase-1 and −2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells, Eur. J. Pharm., 347, 87, 10.1016/S0014-2999(98)00078-8

Kujubu, 1991, TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue, J. Biol. Chem., 266, 12 866, 10.1016/S0021-9258(18)98774-0

Laneuville, 1994, Differential inhibition of human prostaglandin endoperoxide H synthases-1 and −2 by nonsteroidal anti-inflammatory drugs, J. Pharmacol. Exp. Ther., 271, 927

Lanza, 1987, An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa, J. Rheumatol., 14, 338

Lanza, 1999, Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen, Aliment. Pharmacol. Ther., 13, 761, 10.1046/j.1365-2036.1999.00529.x

Laufer, 1999, Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors, Inflamm. Res., 48, 133, 10.1007/s000110050436

Lipscomb, 1998, Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study, Br. J. Clin. Pharmacol., 46, 133, 10.1046/j.1365-2125.1998.00761.x

Masferrer, 1994, Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic, Proc. Natl Acad. Sci., 91, 3228, 10.1073/pnas.91.8.3228

Mitchell, 1994, Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase, Proc. Natl Acad. Sci., 90, 11 693, 10.1073/pnas.90.24.11693

Morita, 1995, Different intracellular locations for prostaglandin endoperoxide H synthase-1 and −2, J. Biol. Chem., 270, 10 902, 10.1074/jbc.270.18.10902

O'Neill, 1993, Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues, FEBS Lett., 330, 156, 10.1016/0014-5793(93)80263-T

Penning, 1997, Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4–[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib), J. Med. Chem., 40, 1347, 10.1021/jm960803q

Riendeau, 1997, Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor, Br. J. Pharmacol., 121, 105, 10.1038/sj.bjp.0701076

Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial, JAMA, 284, 1247, 10.1001/jama.284.10.1247

Simon, 1999, Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial, JAMA, 282, 1921, 10.1001/jama.282.20.1921

Smith, 1998, Pharmacological analysis of cyclooxygenase-1 in inflammation, Proc. Natl Acad. Sci., 95, 13 313, 10.1073/pnas.95.22.13313

Vane, 1971, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nat. New Biol., 231, 232, 10.1038/newbio231232a0

Vane, 1996, Mechanism of action of anti-inflammatory drugs, Scand. J. Rheumatol., 25, 9, 10.3109/03009749609097226

Warner, 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl Acad. Sci., 96, 7563, 10.1073/pnas.96.13.7563

Xie, 1991, Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing, Proc. Natl Acad. Sci., 88, 2692, 10.1073/pnas.88.7.2692

Yamazaki, 1997, Aceclofenac blocks prostaglandin E2 production following its in-tracellular conversion into cyclooxygenase inhibitors, Eur. J. Pharmacol., 329, 181, 10.1016/S0014-2999(97)89179-0

Yamazaki, 1999, Hydrolytic activity is essential for aceclofenac to inhibit cyclo-oxygenase in rheumatoid synovial cells, J. Pharmacol. Exp. Ther., 289, 676